Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
University of Oxford · Oxford Centre for Diabetes, Endocrinology and Metabolism · +12 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
589
total citations
- FWCI
- 50.03
- Percentile
- 100%
- References
- 16
Citations per year
Authors
17- MAM. Angelyn BethelCorresponding
University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism
- RPRishi Patel
University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism
- PMPeter Merrill
Duke University, Clinical Research Institute
- YLYuliya Lokhnygina
Duke University, Clinical Research Institute
- JBJohn B. Buse
University of North Carolina at Chapel Hill
Topics & keywords
Topics
Keywords
- Medicine
- Semaglutide
- Liraglutide
- Lixisenatide
- Exenatide
- Glucagon-like peptide 1 receptor
- Internal medicine
- Type 2 diabetes
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.